Previous 10 | Next 10 |
Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ...
2024-02-22 12:15:13 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2023 Earnings Call Feb 22, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2023 Earnings Call Transcript
2024-02-21 11:34:50 ET More on NovoCure NovoCure: Stay Cautious Amid Positive Signs NovoCure Tumor Treating Fields accepted for FDA review Novocure reports better-than-expected preliminary Q4, FY revenue Seeking Alpha’s Quant Rating on NovoCure ...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-01-19 17:47:40 ET Summary NovoCure's FDA application for TTF in NSCLC accepted; approval expected in H2 2024. Preliminary Q4 results show $509M annual revenue. This is a slight increase from estimates but a 5% year-on-year decline. NovoCure's valuation struggles with tepi...
2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...
NovoCure Limited (NASDAQ: NVCR) is one of today's top gainers. The company's shares have moved 3.24% on the day to $13.05. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company...
2024-01-18 07:24:27 ET More on NovoCure, Zai Lab, etc. Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) NovoCure: Significant Upside Even Without A Breakthrough Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Novocure reports better-tha...
Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after plati...
2024-01-12 16:40:04 ET Gainers: Outset Medical ( OM ) +11% . Kandi Technologies Group ( KNDI ) +7% . Dyne Therapeutics ( DYN ) +5% . Revance Therapeutics ( RVNC ) +4% . NovoCure Limited ( NVCR ) +3% . Losers: Gritstone...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...